Evaluating Reluctance to Embrace Selective Laser Trabeculoplasty as Front-Line Therapy
A growing body of research shows SLT for first-line glaucoma therapy works as well as drops — so why aren’t clinician’s embracing it?
Ophtalmic Disorders
Review: Drugs that Induce Corneal Epithelial Changes
Corneal epithelial changes can be caused by medications in multiple pharmacological classes.
AAO: Age-Related Macular Degeneration Risk Reduced with Mediterranean Diet
Eating a Mediterranean diet and consuming caffeine may lower the risk of age-related macular degeneration (AMD), according to a study presented at the annual meeting of the American Academy of Ophthalmology, held in Chicago.
Study Examines Topotecan-Based Therapy for Advanced Retinoblastoma
For patients with advanced retinoblastoma, topotecan combined with vincristine, carboplatin, and aggressive focal therapies is effective, according to a study published online in the Journal of Clinical Oncology.
FDA to Review Device-Based Approach for Tear Production
Allergan announced the submission of a de novo application to the Food and Drug Administration (FDA) for the Oculeve Intranasal Tear Neurostimulator device.
Male to Female Corneal Transplants May Have Greater Rejection Risk
Women who undergo a corneal transplant may have a worse outcome if their donor is male, according to a study published online July 14 in the American Journal of Transplantation.
First-in-Class Eye Drops Approved to Treat Dry Eye Disease
Shire announced that the Food and Drug Administration (FDA) has approved Xiidra (lifitegrast ophthalmic solution) 5% for the treatment of the signs and symptoms of dry eye disease in adults. This is the first prescription ophthalmic solution approved to treat both signs and symptoms of this condition.
New Jetrea Formulation Eliminates Dilution Step
ThromboGenics announced that the Food and Drug Administration (FDA) has approved a new “already-diluted” formulation of Jetrea (ocriplasmin) intravitreal injection.
Combigan Ophthalmic Solution Available in New Size
Combigan (brimonidine tartrate, timolol maleate; Allergan) ophthalmic solution is now available in a new 15mL bottle size for a 90-day supply.
Number of Visually Impaired Americans Expected to Double by 2050
As baby boomers age, the number of Americans with visual impairment and blindness is expected to double over the next 3 decades, according to a study published online in JAMA Ophthalmology.
